Phase II/III study results confirmed that fexinidazole, DNDi’s first new chemical entity is safe and effective, and presents significant advantages over current treatment as it removes the need for lumbar puncture and systematic patient hospitalization. A regulatory dossier has been submitted to the European Medicines Agency for fexinidazole as the first all-oral treatment for sleeping sickness.
Futurism [19 October, 2017]
“Scientists cured a deadly neurological disease using a revolutionary method”
Nature [18 October, 2017]
“Sleeping sickness can now be cured with pills”
Health Analytics India [17 October, 2017]
“How India can help eliminate neglected diseases”
Radis [1 October, 2017]
“Pessoas negligenciadas, políticas globais” – “Neglected people, global policies”
Combining patient data from visceral leishmaniasis clinical trials would give scientists and clinicians more tools to understand and treat the disease which can be fatal if untreated.
IP Watch [3 July, 2017]
“Enter the African Medicines Agency, continent’s first super-regulator”
Global Health NOW [13 June, 2017]
“Tapping student potential: Q&A on DNDi’s Open Synthesis Network with Ben Perry”
Chemical & Engineering News [15 May, 2017]
“Students seeking drug leads for visceral leishmaniasis”
Chemical & Engineering News [11 May, 2017]
“Developing drugs for tropical diseases: 30 years of Katsura Hata at Eisai”
IP Watch [3 May, 2017]
“New open source project enlists students to find cures for neglected diseases”
October 16-20, 2017
DNDi presented on sleeping sickness, visceral leishmaniasis, mycetoma, and onchocerciasis.
Nikkei [16 March, 2017]
“A drugmaking duo takes the fight to a neglected disease”
October 15-17, 2017
Monique Wasunna, Director of DNDi Africa, presented on strengthening capacity for visceral leishmaniasis clinical research in Africa.
by Wasunna M, Musa, A, Hailu A, Khalil EAG, Olobo J, Juma R, Wells S, Alvar J, Balasegaram M.
Transactions of the Royal Society of Tropical Medicine and Hygiene, June 2016
[Summit, New Jersey and Geneva, Switzerland – June 15, 2016]
First US-based biopharmaceutical partner to join global consortium
The biopharmaceutical company Celgene has become the fifth company to join the “Neglected Tropical Diseases Drug Discovery Booster” consortium, a new initiative to accelerate and cut the cost of early stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease.